Bone defects lead by traumatic injuries, congenital malformations and other surgical rescissions rises the immediate need for a more evolved and safer approaches in tissue repair at alarming rates for the downgrading issues with existing strategies which needs to be addressed. Currently practiced treatment methods addressing the issue with bone defects are invasive, traumatic and are not cost effective. Yet, issues of immune rejection either immediately or in the later stages have been reported claiming its ineffectiveness in some selective case studies.
Previous work by researchers carried out the "Biomimetic" approach to provide the cells with the microenvironment and in situ conditions for the cells seeded into the 3D Osteogenic scaffolds enriched with growth supplments. Here, we address the issue of non-availability of therapeutic cells - a major problem with current translational medicine by proposing the use of Human Embryonic Stem Cells in generating strong and structurally rigid bone tissue. Inducing the production of Mesenchymal Progenitor cells from Human Embryonic Stem cells in Serum supplemented expansion medium and elimination of bone Fibroblast growth factor produced high quality MPCs which were induced in osteogenic medium to result in bone differentiating cells. Culturing these MPCs produced from three different protocols into 3D Scaffold and 3D-Endoret Osteogenic Scaffold produced tissue constructs which are analysed both biochemically and Histologically to check for the Bone tissue differentiation parameters such as Bone sialoprotein deposition, Osteopontin accumulation and Collagen deposition. Matrix mineralization in these constructs were studied by uCT imaging and safety studies were conducted by studying Orthotopic implantation models in SCID mouse. And the results are expected to be optimistically affirmative which shall lay a new foundation and pioneer a whole new approach in the field of Tissue Engineering.